Modeling Stress-precipitated Smoking Behavior for Medication Development

Conditions

Smoking

Trial Phase

Phase II

Trial Purpose and Description

Trial Purpose

The purpose of this study is to examine whether guanfacine or carvedilol will attenuate the ability of stress to precipitate smoking lapse behavior in treatment seeking and non-treatment seeking daily smokers. Participants seeking treatment for smoking will participate in a smoking cessation attempt after the laboratory sessions. Also looking at gender differences.


Participation Guidelines

Age:
18 Years - 60 Years
Gender:
Both

Eligibility Criteria

Inclusion Criteria

  • ages 18-60
  • able to read and write in English
  • smokers

Exclusion Criteria

  • any significant current medical conditions that would contraindicate smoking
  • current DSM-IV abuse or dependence of other substances, other than nicotine (or caffeine) dependence
  • positive test result at intake appointments on urine drug screens conducted for opiates, cocaine, or benzodiazepines
  • women who are pregnant or nursing
  • suicidal, homicidal or evidence of severe mental illness
  • participants prescribed any psychotropic drug in the 30 days prior to study enrollment
  • blood donation within the past 6 weeks
  • participants who have engaged in a quit attempt in the past 3 months
  • specific exclusions for administration of guanfacine/carvedilol not already specified include: Hypotensive individuals with sitting blood pressure below 90/50 mmHG EKG evidence at baseline screening of any clinically significant conduction abnormalities, including a Bazlett's QTc >450 msec for men and QTc>470 msec for women known intolerance for guanfacine
Sponsor:
National Institute on Drug Abuse
Office of Research on Women's Health (ORWH)
Yale University
Dates:
09/27/2008
Last Updated:
Study HIC#:
0808004163